A randomized, double-blind, parallel-group, single-dose comparative pharmacokinetic study of DRL_TZ, a candidate biosimilar of trastuzumab, with Herceptin ® (EU) in healthy adult males.

MLA

Lickliter, Jason D., et al. “A Randomized, Double-Blind, Parallel-Group, Single-Dose Comparative Pharmacokinetic Study of DRL_TZ, a Candidate Biosimilar of Trastuzumab, with Herceptin ® (EU) in Healthy Adult Males.” The Indian Journal of Medical Research, vol. 154, no. 3, Mar. 2021, pp. 509–19. EBSCOhost, https://doi.org/10.4103/ijmr.IJMR_1119_18.

APA

Lickliter, J. D., Dadhania, R. N., Trivedi, R. K., Naveen Kumar, S. R., & Reddy, P. K. (2021). A randomized, double-blind, parallel-group, single-dose comparative pharmacokinetic study of DRL_TZ, a candidate biosimilar of trastuzumab, with Herceptin ® (EU) in healthy adult males. The Indian Journal of Medical Research, 154(3), 509–519. https://doi.org/10.4103/ijmr.IJMR_1119_18

Chicago

Lickliter, Jason D, Rakesh Naranbhai Dadhania, Ravi Kumar Trivedi, S R Naveen Kumar, and Pramod Kumar Reddy. 2021. “A Randomized, Double-Blind, Parallel-Group, Single-Dose Comparative Pharmacokinetic Study of DRL_TZ, a Candidate Biosimilar of Trastuzumab, with Herceptin ® (EU) in Healthy Adult Males.” The Indian Journal of Medical Research 154 (3): 509–19. doi:10.4103/ijmr.IJMR_1119_18.